Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
71.5 kDa after removal of signal peptide. Protein migrates as 100-110 kDa in reduced SDS-PAGE resulting from glycosylation
HEK 293 Cells
Greater than 95% by SDS-PAGE
Measured by its ability to inhibit the biological activity of Neuregulin1-ß1 on MCF-7 human breast cancer cells, in the presence of 10 ng/ml recombinant Human NRG1-ß1/HRG1-ß1 Extracellular Domain. The ED50 for this effect is typically 0.5-3.0 µg/ml
Less than 1.0 EU/µg protein (determined by LAL method).
Lyophilized from PBS, pH 7.4, 5-8% mannitol or trehalose
Centrifuge the vial before opening. Reconstitute in sterile PBS, pH 7.4 to 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, store at -20°C.
ERBB3 / HER3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity.